Skip to main content
SK biopharmaceuticals Co., Ltd. logo

SK biopharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 326030 ISIN · KR7326030004 KO Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country KR South Korea
Listing KO 326030

About SK biopharmaceuticals Co., Ltd.

https://www.skbp.com/

SK biopharmaceuticals is a pharmaceutical company focused on the research, development, and commercialization of innovative treatments, primarily for central nervous system (CNS) disorders. The company's portfolio is led by Cenobamate, an anti-seizure medication for epilepsy that was discovered and developed in-house, and also includes the commercialized product Solriamfetol. Its development pipeline features candidates such as Carisbamate. Strategically, the company is expanding into new therapeutic areas, notably oncology through the development of a Radiopharmaceutical Therapy (RPT) portfolio, and is advancing digital healthcare solutions, including an AI-driven platform for epilepsy management. The company operates as a fully integrated global entity, managing the entire value chain from drug discovery to commercialization.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Regulatory Filings
2026-05-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a "주식등의 대량보유상황보고서(약식)" – a Large Shareholding Report filed by the National Pension Service under Korea’s Capital Market Act, detailing its shareholdings and a change in percentage (e.g., drop of 1.03%). It is a notification of significant share ownership changes (threshold crossing). This matches our “Major Shareholding Notification” category (Code: MRQ).
2026-04-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean statutory ownership report titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” filed with the Financial Services Commission and Korea Exchange. It details shareholdings and transaction amounts by an insider (executive/major shareholder) and specific changes in stock ownership. This matches the definition for “Director’s Dealing” (DIRS), which covers insider share transaction disclosures.
2026-03-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a detailed “주식등의 대량보유상황보고서(일반)” (Large Shareholding Report) in Korean, listing major share ownership changes, reporting thresholds crossed, share counts, percentages, and related contractual details. This matches the definition of Major Shareholding Notification (code MRQ).
2026-03-31 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 1% confidence The document is a Korean "최대주주등소유주식변동신고서" (Notice of changes in ownership of shares by major shareholders and related parties). It details share counts before and after the reporting date, ownership ratios, and individual transactions by the major shareholder and certain executives. This clearly corresponds to a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels.
2026-03-31 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 0% confidence The document is a brief disclosure of the execution of a single sales and supply contract (단일판매ㆍ공급계약 체결) between SK Biopharm and its subsidiary SK Life Science, Inc. It does not present full financial statements, management analysis, or ESG information; it is not an earnings release, share transaction, or M&A activity. No specific category (e.g., CAP for financing, TAR for M&A) fits a standard sales contract announcement. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.